Stock Events

Stock Events

Elicio Therapeutics 

$3.04
40
-$0.04-1.14% Friday 20:00
+$0.09+2.96%Friday 23:59After hours

Statistics

Day High
3.05
Day Low
3.03
52W High
16
52W Low
2.66
Volume
10,043
Avg. Volume
-
Mkt Cap
79.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.39
-1.07
-0.75
-0.43
Expected EPS
-0.479825
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-39.57MNet Income

Analyst Ratings

19.75Average Price Target
The highest estimate is 27.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELTX. It's not an investment recommendation.
Microsoft
9
MSFT
NVIDIA
9
NVDA
Nike
9
NKE
Apple
8
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap25.28B
Moderna Inc. focuses on mRNA-based therapies, including cancer vaccines, directly competing with Elicio's amphiphile technology in cancer immunotherapy.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech SE develops targeted cancer therapies using mRNA, similar to Elicio's approach in stimulating robust immune responses against cancer.
Novavax
NVAX
Mkt Cap1.33B
Novavax, Inc. is involved in the development of vaccines, including for cancer, which competes with Elicio's cancer vaccine platforms.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. has a strong portfolio in oncology and cell therapy, areas where Elicio is also trying to make an impact.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. works on innovative therapeutics in oncology, including immune-oncology, a field where Elicio is also active.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol-Myers Squibb Company offers immunotherapy treatments for cancer, competing with Elicio's cancer immunotherapies.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a leader in cancer immunotherapy with products like Keytruda, competing in the same space as Elicio's therapies.
Pfizer
PFE
Mkt Cap152.69B
Pfizer Inc. develops and markets drugs and vaccines, including cancer treatments, which overlaps with Elicio's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals, Inc. is known for its innovative biopharmaceuticals targeting various diseases, including cancer, similar to Elicio's focus.
Novartis
NVS
Mkt Cap286.78B
Novartis AG has a broad focus in healthcare, including advanced therapies in oncology, competing with Elicio's cancer treatment technologies.

About

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Show more...
CEO
Robert T. Connelly
Employees
33
Country
United States
ISIN
US28657F1030
WKN
000A3CY4J

Listings

MU
DE
9HA.MU
MU
DE
5YX.MU
STU
DE
9HA.STU
STU
DE
5YX.STU

0 Comments

Share your thoughts

FAQ

What is Elicio Therapeutics stock price today?▼
The current price of ELTX is $3.04 USD — it has decreased by -1.14% in the past 24 hours. Watch Elicio Therapeutics stock price performance more closely on the chart.
What is Elicio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Elicio Therapeutics stocks are traded under the ticker ELTX.
Is Elicio Therapeutics stock price growing?▼
ELTX stock has fallen by -1.62% compared to the previous week, the month change is a -2.56% fall, over the last year Elicio Therapeutics has showed a -74.24% decrease.
What is Elicio Therapeutics market cap?▼
Today Elicio Therapeutics has the market capitalization of 79.9M
When is the next Elicio Therapeutics earnings date?▼
Elicio Therapeutics is going to release the next earnings report on November 13, 2026.
What were Elicio Therapeutics earnings last quarter?▼
ELTX earnings for the last quarter are -0.43 USD per share, whereas the estimation was -0.54 USD resulting in a +20% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Elicio Therapeutics revenue for the last year?▼
Elicio Therapeutics revenue for the last year amounts to 0 USD.
What is Elicio Therapeutics net income for the last year?▼
ELTX net income for the last year is -39.57M USD.
How many employees does Elicio Therapeutics have?▼
As of August 22, 2026, the company has 33 employees.
In which sector is Elicio Therapeutics located?▼
Elicio Therapeutics operates in the Health & Wellness sector.
When did Elicio Therapeutics complete a stock split?▼
Elicio Therapeutics has not had any recent stock splits.
Where is Elicio Therapeutics headquartered?▼
Elicio Therapeutics is headquartered in BOSTON, United States.